VYGR - Voyager Therapeutics, Inc.
About Voyager Therapeutics, Inc. (https://www.voyagertherapeutics.com)
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Alfred W. Sandrock Jr. | President, Chief Executive Officer & Director | 1958 | $1,052,570 USD |
| Robin Swartz | Principal Financial Officer, Treasurer, Chief Business Officer & COO | 1971 | $738,950 USD |
| Nathan D. Jorgensen | Chief Financial Officer | 1977 | $577,748 USD |
| Amy Quinlan | Principal Accounting Officer | 1975 | – |
| Gregory Shiferman | Senior VP, General Counsel & Secretary | 1985 | – |
| Krystof Bankiewicz | Founder | – | – |
| Mark A. Kay | Founder | 1959 | – |
| Mathieu Nonnenmacher | Vice President of Gene Therapy | – | – |
| Todd Carter | Chief Scientific Officer | 1970 | – |
| Trista Morrison | Chief Corporate Affairs Officer & Chief of Staff to the Chief Executive Officer | 1977 | – |